Business
PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom's Ability to Eradicate Cancer Cells as Continued Support for PetLife's pre- INAD Studies of Vitalzul™
PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom's Ability to Eradicate Cancer Cells as Continued Support for PetLife's pre- INAD Studies of Vitalzul™.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n\n Hancock, MD, Nov. 15, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the \"Company\"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, has been pleased with the existing studies coming out of Cuba and is looking forward to additional research of the benefits of Blue Scorpion venom. The market for natural products for human Cancer treatment has been big business in Cuba.\n Cuban researchers have published studies demonstrating the efficacy of the venom extract of the blue scorpion (Rhopalurus junceus) in the Journal of Venom Research (1). This human study demonstrates the efficacy across many Cancer Cell lines. Additional studies have been undertaken to characterize Rhopalurus junceus venom in other international journals (2), (3), (4). These studies support the efforts of PetLife Pharmaceuticals to bring an FDA/CVM approved, prescription strength, clinically proven Blue scorpion venom product to market for the treatment of cancer in companion animals, Vitalzul™. Dr. Salvagno, CEO of PetLife Pharmaceuticals noted “PetLife will continue on our path, through our current pre-INAD studies and subsequent application to the FDA/CVM, to secure approval of our patented prescription strength formulation of blue scorpion venom “Vitalzul™”. These studies from Cuba support our work, but we will clearly move forward with appropriate studies to confirm efficacy, dosing and safety to allow distribution of a therapeutic drug to the US and international markets.”  These manuscripts can be found on our website www.petlifepharma.com PetLife’s 506 Private Placement Memorandum is available only to accredited investors.  In Vitro anticancer effect of Venom from Cuban Scorpion Rhopalurus junceus against a panel of human cancer cell lines. Diaz-Garcia et al. J Venom research (2013), Vol. 4, 5-12 Enzymatic analysis of venom from Cuban scorpion Rhopalurus junceus. J Venom Research (2015), Vol. 6, 11-18 Biochemical and molecular characterization of the venom from the Cuban Scorpion Rhopalurus junceus. Garcia-Gomez et al. Toxicon (2011), Vol. 58, 18-27 The Cuban scorpion Rhopalurus junceus (Scorpion Buthidae): component variations in venom samples collected in different geographic areas. Rodriguez-Ravelo et al. J Venom ...